P61585 (RHOA_BOVIN) Bos taurus (Bovine)
Transforming protein RhoA UniProtKBInterProSTRINGInteractive Modelling
193 aa; Sequence (Fasta) ;
109 identical sequences
Available Structures
124 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Farnesylated RhoA-GDP in complex with RhoGDI-alpha, lysine acetylated at K178 |
Heteromer P19803; P61586; | 100.0 | 1×FAR; 1×GDP; 1×MG; 1×BGC; | |||
| Double acetylated RhoGDI-alpha in complex with RhoA-GDP |
Heteromer P19803; P61586; | 100.0 | 1×GDP; 3×MG; | |||
| Cryo-EM structure of the human TRPV4 - RhoA in complex with GSK2798745 |
Heteromer P61586; Q9HBA0; | 100 | 4×XPW; 4×MG; 4×GDP; | |||
| Cryo-EM structure of the human TRPV4 - RhoA, apo condition |
Heteromer P61586; Q9HBA0; | 100 | 4×MG; 4×GDP; | |||
| Cryo-EM structure of the human TRPV4 - RhoA in complex with GSK1016790A |
Heteromer P61586; Q9HBA0; | 100 | 4×XQ3; 4×Y01; 4×GSP; | |||
| Crystal structure of SmgGDS-558 and farnesylated RhoA complex |
Heteromer P52306; P61586; | 100.0 | 1×FAR; | |||
| CRYSTAL STRUCTURE OF THE RHOA.GDP-RHOGDI COMPLEX |
Heteromer P52565; P61586; | 99.47 | 1×MG; 1×GDP; | |||
| Structure of human TRPV4 with antagonist A2 and RhoA |
Heteromer P61586; Q9HBA0; | 100 | 4×F9M; | |||
| A Complex between PH Domain of p114RhoGEF and Activated RhoA Bound to a GTP Analog |
Heteromer P61586; Q6P9R4; | 100 | 1×GSP; 1×MG; 1×EDO; | |||
| Crystal Structure of RhoA-GDP-Pi in Complex with RhoGAP |
Heteromer P61586; Q07960; | 100.0 | 2×PO4; 1×MES; 1×GDP; 1×MG; 1×DTT; | |||
| CRYSTAL STRUCTURE OF HUMAN RHOA COMPLEXED WITH THE EFFECTOR DOMAIN OF THE PROTEIN KINASE PKN/PRK1 |
Heteromer P61586; Q16512; | 99.45 | 1×MG; 1×GSP; | |||
| Cryo-EM structure of human TRPV4 ankyrin repeat domain in complex with GTPase RhoA |
Heteromer P61586; Q9HBA0; | 100.0 | 1×GDP; | |||
| Shigella IpgB2 in complex with human RhoA and GDP (complex C) |
Heteromer P61586; Q9AJW7; | 100 | 1×GDP; 3×SO4; | |||
| Shigella IpgB2 in complex with human RhoA, GDP and Mg2+ (complex A) |
Heteromer P61586; Q9AJW7; | 100 | 1×GDP; 1×MG; | |||
| Shigella IpgB2 in complex with human RhoA, GDP and Mg2+ (complex B) |
Heteromer P61586; Q9AJW7; | 100 | 1×GDP; 1×MG; | |||
| Crystal Structure of the DH/PH domains of Leukemia-associated RhoGEF in complex with RhoA |
Heteromer P61586; Q9NZN5; | 100 | 1×PO4; | |||
| Cryo-EM structure of the human TRPV4-RhoA in complex with AH001 |
Heteromer P61586; Q9HBA0; | 100 | 2×P5S; 2×U6L; 2×GDP; 2×MG; | |||
| Cryo-EM structure of human TRPV4 intracellular domain in complex with GTPase RhoA |
Heteromer P61586; Q9HBA0; | 100 | 1×GDP; 1×MG; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z108545814 |
Heteromer P61586; Q92974; | 100 | 2×YX2; 4×DMS; 14×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1273312142 |
Heteromer P61586; Q92974; | 100 | 5×DMS; 14×FMT; 1×Z4X; | |||
| The DH domain of ARHGEF2 bound to RhoA |
Heteromer P61586; Q92974; | 100 | 5×DMS; 15×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1079512010 |
Heteromer P61586; Q92974; | 100 | 3×UWS; 5×DMS; 15×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1079168976 |
Heteromer P61586; Q92974; | 100 | 1×YXK; 4×DMS; 10×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z100643660 |
Heteromer P61586; Q92974; | 100 | 4×LFO; 4×DMS; 14×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1270087714 |
Heteromer P61586; Q92974; | 100 | 1×Z5Z; 5×DMS; 13×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z100642432 |
Heteromer P61586; Q92974; | 100 | 1×WJ7; 5×DMS; 15×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z104474512 |
Heteromer P61586; Q92974; | 100 | 2×H04; 4×DMS; 12×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1269220427 |
Heteromer P61586; Q92974; | 100 | 2×Z2Z; 5×DMS; 13×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1198180782 |
Heteromer P61586; Q92974; | 100 | 3×YXU; 8×DMS; 12×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1041785508 |
Heteromer P61586; Q92974; | 100 | 1×K34; 3×DMS; 13×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1137725943 |
Heteromer P61586; Q92974; | 100 | 3×YXB; 6×DMS; 10×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z111529496 |
Heteromer P61586; Q92974; | 100 | 2×LXA; 6×DMS; 13×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z104479710 |
Heteromer P61586; Q92974; | 100 | 5×DMS; 12×FMT; 1×YXH; | |||
| Crystal Structure of RhoA.GDP.MgF3-in Complex with RhoGAP |
Heteromer P61586; Q07960; | 99.44 | 1×MG; 1×GDP; 1×MGF; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1102357527 |
Heteromer P61586; Q92974; | 100 | 1×YX6; 4×DMS; 11×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1148747945 |
Heteromer P61586; Q92974; | 100 | 1×WKY; 5×DMS; 10×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1192341021 |
Heteromer P61586; Q92974; | 100 | 2×ZT7; 4×DMS; 9×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z111529496 |
Heteromer P61586; Q92974; | 100 | 2×LXA; 5×DMS; 12×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102209-001 |
Heteromer P61586; Q92974; | 100 | 4×DMS; 10×FMT; 1×ZGF; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z104474228 |
Heteromer P61586; Q92974; | 100 | 5×DMS; 12×FMT; 3×60P; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1416193393 |
Heteromer P61586; Q92974; | 100 | 1×Z6I; 5×DMS; 13×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1216861874 |
Heteromer P61586; Q92974; | 100 | 1×YYI; 4×DMS; 8×FMT; | |||
| A Complex between PH Domain of LbcRhoGEF (AKAP-Lbc) and Activated RhoA Bound to a GTP Analog |
Heteromer P61586; Q12802; | 100 | 1×MG; 1×GSP; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1148165337 |
Heteromer P61586; Q92974; | 100 | 1×YG5; 5×DMS; 14×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102236-001 |
Heteromer P61586; Q92974; | 100 | 3×DMS; 11×FMT; 1×ZGK; | |||
| AKAP13 (AKAP-Lbc) RhoGEF domain in complex with RhoA |
Heteromer P61586; Q12802; | 100 | 1×GDP; 5×SO4; 1×EDO; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102197-001 |
Heteromer P61586; Q92974; | 100 | 5×DMS; 10×FMT; 1×ZG6; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1037511924 |
Heteromer P61586; Q92974; | 100 | 1×YXO; 5×DMS; 10×FMT; | |||
| A Complex between PH Domain of p190RhoGEF and Activated RhoA Bound to a GTP Analog |
Heteromer P61586; Q8N1W1; | 100 | 1×MG; 1×GSP; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102253-001 |
Heteromer P61586; Q92974; | 100 | 1×ZGQ; 4×DMS; 10×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1269184613 |
Heteromer P61586; Q92974; | 100 | 1×Z2F; 3×DMS; 7×FMT; | |||
| Transition state analogue of small G protein in complex with relevant GAP |
Heteromer P61586; Q07960; | 98.88 | 2×GDP; 2×MGF; 2×MG; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1262549981 |
Heteromer P61586; Q92974; | 100 | 1×Z1L; 3×DMS; 11×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1198316457 |
Heteromer P61586; Q92974; | 100 | 1×YXY; 3×DMS; 11×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102116-001 |
Heteromer P61586; Q92974; | 100 | 2×DMS; 7×FMT; 1×ZG0; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102113-001 |
Heteromer P61586; Q92974; | 100 | 2×DMS; 11×FMT; 1×ZEK; | |||
| Structure of TcdA GTD in complex with RhoA |
Heteromer P16154; P61586; | 99.44 | 1×UPG; 1×MN; 1×SO4; 1×GDP; 1×MG; | |||
| Crystal structure of the complex between the human RhoA and Rho-binding domain of human ROCKI |
Heteromer P61586; Q13464; | 100 | 2×MG; 2×GNP; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102179-001 |
Heteromer P61586; Q92974; | 100 | 2×DMS; 9×FMT; 1×T7Y; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102141-001 |
Heteromer P61586; Q92974; | 100 | 4×DMS; 8×FMT; 2×ZFI; | |||
| Crystal Structure of the Complex of PDZ-RhoGEF DH/PH domains with GTP-gamma-S Activated RhoA |
Heteromer O15085; P61586; | 100 | 1×MG; 1×GSP; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102245-001 |
Heteromer P61586; Q92974; | 100 | 2×DMS; 7×FMT; 1×KLU; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z133716556 |
Heteromer P61586; Q92974; | 100 | 1×Z3H; 5×DMS; 14×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1575337975 |
Heteromer P61586; Q92974; | 100 | 3×ZC9; 4×DMS; 13×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1217131798 |
Heteromer P61586; Q92974; | 100 | 3×YZK; 6×DMS; 14×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1493056027 |
Heteromer P61586; Q92974; | 100 | 7×DMS; 14×FMT; 1×Z9I; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z165170770 |
Heteromer P61586; Q92974; | 100 | 4×W0Y; 5×DMS; 11×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1267800292 |
Heteromer P61586; Q92974; | 100 | 3×O2A; 4×DMS; 12×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1251207602 |
Heteromer P61586; Q92974; | 100 | 4×RWS; 6×DMS; 13×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1270393711 |
Heteromer P61586; Q92974; | 100 | 3×Z5C; 5×DMS; 13×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1565771450 |
Heteromer P61586; Q92974; | 100 | 2×VW7; 5×DMS; 10×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1416571195 |
Heteromer P61586; Q92974; | 100 | 1×Z7T; 5×DMS; 12×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1449748885 |
Heteromer P61586; Q92974; | 100 | 1×WZY; 5×DMS; 14×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102102-001 |
Heteromer P61586; Q92974; | 100 | 2×ZE9; 6×DMS; 13×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1545313172 |
Heteromer P61586; Q92974; | 100 | 1×LWA; 5×DMS; 14×FMT; | |||
| GTPase IN COMPLEX WITH GDP.MGF3- |
Heteromer P61586; Q07960; | 98.87 | 2×GDP; 2×MGF; 2×MG; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1509195674 |
Heteromer P61586; Q92974; | 100 | 1×ZA9; 5×DMS; 11×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102281-001 |
Heteromer P61586; Q92974; | 100 | 1×ZGX; 5×DMS; 11×FMT; | |||
| CRYSTAL STRUCTURE OF HUMAN RHOA IN COMPLEX WITH DH/PH FRAGMENT OF THE GUANINE NUCLEOTIDE EXCHANGE F… |
Heteromer P61586; Q7Z628; | 99.42 | ||||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1255459547 |
Heteromer P61586; Q92974; | 100 | 1×Z0I; 3×DMS; 12×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1509257513 |
Heteromer P61586; Q92974; | 100 | 1×ZBH; 3×DMS; 11×FMT; | |||
| Crystal structure of the ternary complex between the human RhoA, its inhibitor and the DH/PH domain… |
Heteromer O15085; P61586; | 100 | 2×GOL; 1×RA0; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z57899718 |
Heteromer P61586; Q92974; | 100 | 1×APY; 3×DMS; 1×FMT; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1203730981 |
Heteromer P61586; Q92974; | 100 | 2×ZCI; 3×DMS; 9×FMT; | |||
| Crystal Structure of human RhoGAP mutated in its arginine finger (R85A) in complex with RhoA.GDP.Mg… |
Heteromer P61586; Q07960; | 99.44 | 1×MG; 1×GDP; 1×MGF; | |||
| Crystal Structure of RhoA.GDP.MgF3-in complex with human Myosin 9b RhoGAP domain |
Heteromer P61586; Q13459; | 99.44 | 1×MGF; 1×MG; 1×GDP; | |||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z131833926 |
Heteromer P61586; Q92974; | 100 | 3×DMS; 6×FMT; 1×Z3O; | |||
| Crystal Structure of Human RhoA in complex with DH/PH fragment of PDZRHOGEF |
Heteromer O15085; P61586; | 99.44 | ||||
| Crystal structure of the complex between the human RhoA and the DH/PH domain of human ARHGEF11 |
Heteromer O15085; P61586; | 100 | 3×GOL; | |||
| Crystal Structure of the Dbl and Pleckstrin homology domains of Dbs in complex with RhoA |
Heteromer P61586; Q64096; | 100 | ||||
| Crystal Structure of the DH/PH fragment of PDZRHOGEF with N-terminal regulatory elements in complex… |
Heteromer O15085; P61586; | 99.44 | ||||
| ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z4605084898 |
Heteromer P61586; Q92974; | 100 | 2×DMS; 4×FMT; 1×ZDL; | |||
| Cryo-EM structure of Phospholipase C epsilon PH-C terminus in complex with RhoA-GTP |
Heteromer P61586; Q99P84; | 100 | 1×CA; 1×GTP; 1×MG; | |||
| Crystal structure of RhoA.GDP.MgF3 in complex with GAP domain of ArhGAP20 |
Heteromer P61586; Q9P2F6; | 99.44 | 1×GDP; 1×MG; 1×MGF; | |||
| RHO/RHOGAP/GDP(DOT)ALF4 COMPLEX |
Heteromer P61586; Q07960; | 99.42 | 1×MG; 1×ALF; 1×GDP; | |||
| p190A GAP domain complex with RhoA |
Heteromer P61586; P81128; | 99.41 | 2×CL; 1×GDP; 1×MG; 1×MGF; | |||
| Structure of hsAnillin bound with RhoA(Q63L) at 2.1 Angstroms resolution |
Heteromer P61586; Q9NQW6; | 98.87 | 1×GTP; 1×MG; | |||
| The complex structure of C3cer exoenzyme and GTP bound RhoA (NADH-bound state) |
Heteromer P61586; Q8KNY0; | 99.44 | 1×GSP; 1×MG; 1×NAI; 3×EDO; | |||
| The complex structure of C3cer exoenzyme and GDP bound RhoA (NADH-bound state) |
Heteromer P61586; Q8KNY0; | 99.44 | 1×GDP; 1×MG; 1×NAI; 2×EDO; | |||
| Crystal Structure of p63RhoGEF complex with Galpha-q and RhoA |
Heteromer P21279; P61586; Q86VW2; | 100 | 2×ALF; 2×MG; 2×GDP; | |||
| The complex structure of C3cer exoenzyme and GTP bound RhoA (NADH-free state) |
Heteromer P61586; Q8KNY0; | 99.43 | 1×GSP; 1×MG; 2×EDO; | |||
| Crystal Structure of human RhoGAP mutated in its arginin finger (R85A) in complex with RhoA.GDP.AlF… |
Heteromer P61586; Q07960; | 99.42 | 1×MG; 1×GDP; 1×ALF; | |||
| Crystal structure of the fusion protein linked by RhoA and the GAP domain of MgcRacGAP | monomer | 100.0 | 1×MG; 1×AF3; 1×GDP; | |||
| Crystal structure of tumor related RhoA mutant A161V in complex with GDP | monomer | 98.89 | 1×GDP; 1×MG; 2×DIO; | |||
| An open conformation Form 1 of switch II for RhoA | monomer | 97.78 | 1×GDP; 1×MG; | |||
| An open conformation Form2 of switch II for RhoA GDP-bound state | monomer | 97.78 | 1×GOL; 1×GDP; 1×MG; | |||
| Crystal structure of RhoA-GDP with novel Switch I conformation | monomer | 99.44 | 1×GDP; 1×MG; 2×DIO; | |||
| RhoA GDP with novel switch II conformation | monomer | 99.44 | 1×MG; 1×GDP; | |||
| Crystal structure of an inactive state of GMPPNP-bound RhoA | monomer | 99.44 | 1×GNP; 1×MG; 2×DIO; | |||
| Crystal structure of oncogenic RhoA mutant G14V complexed with GDP | monomer | 98.88 | 1×GDP; 1×MG; 2×DIO; | |||
| Crystal structure of tumor related RhoA mutant A161P in complex with GDP | monomer | 98.88 | 1×GDP; 1×MG; 1×DIO; | |||
| Crystal structure of RhoA mutant L69P complexed with GDP | monomer | 99.44 | 1×GDP; 1×MG; | |||
| Crystallization and preliminary X-ray crystallographic analysis of a small GTPase RhoA | monomer | 100 | 3×MG; 1×GDP; | |||
| Crystal structure of RhoA protein with covalent inhibitor DC-Rhoin | monomer | 97.66 | 1×GDP; 1×8ZO; | |||
| RhoGAP domain of ARAP3 in complex with RhoA in the transition state | monomer | 99.39 | 1×GDP; 1×MG; 1×ALF; | |||
| Crystal structure of RhoA mutant L69R complexed with GDP | monomer | 99.44 | 1×GDP; 1×MG; | |||
| Small GTPase RhoA Y42C mutant in complex with GDP | monomer | 99.42 | 1×GDP; 1×MG; | |||
| Crystal structure of Yersinia Afp18-modified RhoA | monomer | 100 | 1×GDP; 1×SO4; 1×NDG; | |||
| CRYSTAL STRUCTURE OF A MG-FREE FORM OF RHOA COMPLEXED WITH GDP | monomer | 97.19 | 1×GDP; | |||
| Samll GTPase RhoA Y42C mutant in complex with GTP analogue | monomer | 99.44 | 1×GNP; 1×MG; | |||
| HUMAN RHOA COMPLEXED WITH GTP ANALOGUE | monomer | 99.44 | 1×MG; 1×GSP; | |||
| Crystal structure of GDP bound RhoA protein | monomer | 97.74 | 1×GDP; | |||
| Crystal Structure of a Constitutively Activated RhoA Mutant (Q63L) | monomer | 98.87 | 2×MG; 1×GNP; 2×DIO; | |||
| CRYSTAL STRUCTURE OF THE HUMAN RHOA/GDP COMPLEX | monomer | 99.44 | 1×MG; 1×GDP; | |||
1 SWISS-MODEL model
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 5fr1.1.A | monomer | 0.83 | 1×GDP; | 100.00 | ||